Systems Pharmacology and Pharmacodynamics

While systems biology and pharmacodynamics have evolved in parallel, there are significant interrelationships that can enhance drug discovery and enable optimized therapy for each patient. Systems pharmacology is the relatively new discipline that is the interface between these two methods. This book is the first to cover the expertise from systems biology and pharmacodynamics researchers, describing how systems pharmacology may be developed and refined further to show practical applications in drug development. There is a growing awareness that pharmaceutical companies should reduce the high attrition in the pipeline due to insufficient efficacy or toxicity found in proof-of-concept and/or Phase II studies. Systems Pharmacology and Pharmacodynamics discusses the framework for integrating information obtained from understanding physiological/pathological pathways (normal body function system vs. perturbed system due to disease) and pharmacological targets in order to predict clinical efficacy and adverse events through iterations between mathematical modeling and experimentation.

Auteur
Donald E. Mager is a Professor of Pharmaceutical Sciences at the University at Buffalo, State University of New York. He also served as a Visiting Professor at the University Paris Descartes in January from 20072013 and 2016. He currently serves on the Clinical Pharmacology Advisory Committee to the FDA and the Editorial Advisory Boards of several journals. Dr. Mager also serves as an Associate or Consulting Editor at CPT:Pharmacometrics & Systems Pharmacology (CPT:PSP), Journal of Pharmacology & Experimental Therapeutics (JPET), and Pharmacology, Research & Perspectives (PRP). He is a former President of the International Society of Pharmacometrics and is a Fellow and member of the Board of Regents of the American College of Clinical Pharmacology. In addition, he is an expert member of the Board of Pharmaceutical Sciences at FIP and serves on the Scientic Advisory Board to Simcyp. His research focuses on identifying molecular and physiological factors that control the pharmacological properties of various drugs, with a focus on anti-cancer and immunomodulatory agents. He has contributed to 120+ peer-reviewed publications.
Holly H.C. Kimko-SA"> is a senior pharmacometrician in the Global Clinical Pharmacology department at Janssen Research & Development, LLC, Spring House, PA, and Adjunct Associate Professor in the Pharmacy School of Rutgers University, New Jersey. Dr. Kimko is a Janssen Research Fellow and American Association of Pharmaceutical Scientists Fellow. She championed the use of modeling and simulations in drug development at the Center for Drug Development Science at Georgetown University Medical School, Washington, DC in 19952002. Trained in biochemistry and pharmacy, Dr. Kimko earned her Ph.D. degree in pharmaceutical sciences from the University at Buffalo, State University of New York. She has published key papers on physiologically-based indirect response modeling and applications of clinical trial simulations and has edited two books on clinical trial simulations. Her research interests include strategic application of modeling and simulation tools in all aspects of drug development and post-approval life cycle management. Among her scientic endeavors is a specialty in pediatric drug development.

Texte du rabat
While systems biology and pharmacodynamics have evolved in parallel, there are significant interrelationships that can enhance drug discovery and enable optimized therapy for each patient. Systems pharmacology is the relatively new discipline that is the interface between these two methods. This book is the first to cover the expertise from systems biology and pharmacodynamics researchers, describing how systems pharmacology may be developed and refined further to show practical applications in drug development. There is a growing awareness that pharmaceutical companies should reduce the high attrition in the pipeline due to insufficient efficacy or toxicity found in proof-of-concept and/or Phase II studies. Systems Pharmacology and Pharmacodynamics discusses the framework for integrating information obtained from understanding physiological/pathological pathways (normal body function system vs. perturbed system due to disease) and pharmacological targets in order to predict clinical efficacy and adverse events through iterations between mathematical modeling and experimentation.

Contenu
Role of Systems Modeling in Regulatory Drug Approval.- Quantitative Systems Pharmacology: Applications and Adoption in Drug Development.- Systems Pharmacology: An Overview.- Discrete dynamic modeling: a network approach for systems pharmacology.- Kinetic Models of Biochemical Signaling Networks.- Mechanistic Models of Physiological Control Systems.- Foundations of Pharmacodynamic Systems Analysis.- Direct, Indirect, and Signal Transduction Response Modeling.- Irreversible Pharmacodynamics.- Feedback Control Indirect Response Models.- Nonlinear Mixed Effects Modeling in Systems Pharmacology.- Detecting Pharmacokinetic and Pharmacodynamic Covariates From High-Dimensional Data.- Multi-Scale Modeling of Drug Action in the Nervous System.- Mechanistic Modeling of Inflammation.- Systems Pharmacology of Tyrosine Kinase Inhibitor-Associated Toxicities.- Translational Modeling of Antibacterial Agents.- Viral DynamicModeling of Hepatitis C Virus Infection: Past Successes and Future Challenges.- Using Systems Pharmacology to Advance Oncology Drug Development.- Systems Pharmacology Modeling in Type 2 Diabetes Mellitus.